A detailed history of Northern Trust Corp transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 465,682 shares of VTYX stock, worth $1.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
465,682
Previous 394,060 18.18%
Holding current value
$1.04 Million
Previous $910,000 11.54%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.85 - $3.2 $132,500 - $229,190
71,622 Added 18.18%
465,682 $1.02 Million
Q2 2024

Aug 14, 2024

SELL
$2.31 - $5.59 $6,969 - $16,865
-3,017 Reduced 0.76%
394,060 $910,000
Q1 2024

May 14, 2024

SELL
$1.9 - $10.13 $107,612 - $573,742
-56,638 Reduced 12.48%
397,077 $2.18 Million
Q4 2023

Feb 13, 2024

BUY
$2.08 - $31.18 $72,336 - $1.08 Million
34,777 Added 8.3%
453,715 $1.12 Million
Q3 2023

Nov 13, 2023

BUY
$29.8 - $40.3 $1.06 Million - $1.43 Million
35,581 Added 9.28%
418,938 $14.5 Million
Q2 2023

Aug 11, 2023

BUY
$28.53 - $39.55 $4.61 Million - $6.39 Million
161,613 Added 72.88%
383,357 $12.6 Million
Q1 2023

May 15, 2023

BUY
$29.51 - $46.65 $167,557 - $264,878
5,678 Added 2.63%
221,744 $7.43 Million
Q4 2022

Feb 13, 2023

BUY
$24.16 - $36.38 $776,260 - $1.17 Million
32,130 Added 17.47%
216,066 $7.08 Million
Q3 2022

Nov 14, 2022

BUY
$12.64 - $38.7 $218,583 - $669,239
17,293 Added 10.38%
183,936 $6.42 Million
Q2 2022

Aug 12, 2022

BUY
$11.95 - $18.75 $960,672 - $1.51 Million
80,391 Added 93.2%
166,643 $2.04 Million
Q1 2022

May 13, 2022

SELL
$10.0 - $19.98 $71,130 - $142,117
-7,113 Reduced 7.62%
86,252 $1.17 Million
Q4 2021

Feb 08, 2022

BUY
$14.2 - $23.07 $1.33 Million - $2.15 Million
93,365 New
93,365 $1.85 Million

Others Institutions Holding VTYX

About Ventyx Biosciences, Inc.


  • Ticker VTYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,527,200
  • Market Cap $127M
  • Description
  • Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...
More about VTYX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.